150 related articles for article (PubMed ID: 38701823)
1. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
Ares-Gómez S; Mallah N; Santiago-Pérez MI; Pardo-Seco J; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; Malvar-Pintos A; González-Pérez JM; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F;
Lancet Infect Dis; 2024 Apr; ():. PubMed ID: 38701823
[TBL] [Abstract][Full Text] [Related]
2. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
Mallah N; Ares-Gómez S; Pardo-Seco J; Malvar-Pintos A; Santiago-Pérez MI; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; González-Pérez JM; Rodríguez-Tenreiro C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F
Hum Vaccin Immunother; 2024 Dec; 20(1):2348135. PubMed ID: 38738683
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study.
Ezpeleta G; Navascués A; Viguria N; Herranz-Aguirre M; Juan Belloc SE; Gimeno Ballester J; Muruzábal JC; García-Cenoz M; Trobajo-Sanmartín C; Echeverria A; Martínez-Baz I; Vera-Punzano N; Casado I; López-Mendoza H; Ezpeleta C; Castilla J
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675765
[TBL] [Abstract][Full Text] [Related]
5. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
Drysdale SB; Cathie K; Flamein F; Knuf M; Collins AM; Hill HC; Kaiser F; Cohen R; Pinquier D; Felter CT; Vassilouthis NC; Jin J; Bangert M; Mari K; Nteene R; Wague S; Roberts M; Tissières P; Royal S; Faust SN;
N Engl J Med; 2023 Dec; 389(26):2425-2435. PubMed ID: 38157500
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
Garegnani L; Styrmisdóttir L; Roson Rodriguez P; Escobar Liquitay CM; Esteban I; Franco JV
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013757. PubMed ID: 34783356
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.
Shoukat A; Abdollahi E; Galvani AP; Halperin SA; Langley JM; Moghadas SM
Lancet Reg Health Am; 2023 Dec; 28():100629. PubMed ID: 38026446
[TBL] [Abstract][Full Text] [Related]
8. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
López-Lacort M; Muñoz-Quiles C; Mira-Iglesias A; López-Labrador FX; Mengual-Chuliá B; Fernández-García C; Carballido-Fernández M; Pineda-Caplliure A; Mollar-Maseres J; Shalabi Benavent M; Sanz-Herrero F; Zornoza-Moreno M; Pérez-Martín JJ; Alfayate-Miguelez S; Pérez Crespo R; Bastida Sánchez E; Menasalvas-Ruiz AI; Téllez-González MC; Esquiva Soto S; Del Toro Saravia C; Sanz-Muñoz I; Eiros JM; Matías Del Pozo V; Toquero-Asensi M; Pastor-Villalba E; Lluch-Rodrigo JA; Díez-Domingo J; Orrico-Sánchez A
Euro Surveill; 2024 Feb; 29(6):. PubMed ID: 38333937
[TBL] [Abstract][Full Text] [Related]
9. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
[TBL] [Abstract][Full Text] [Related]
10. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
[TBL] [Abstract][Full Text] [Related]
11. Hospitalisation of late preterm infants due to lower respiratory tract infections in Lithuania, Latvia, and Estonia: incidence, disease severity, and risk factors.
Drazdienė N; Tamelienė R; Kviluna D; Saik P; Saik E; Zaikauskienė J
Acta Med Litu; 2018; 25(2):76-85. PubMed ID: 30210241
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
[TBL] [Abstract][Full Text] [Related]
13. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
Ernst C; Bejko D; Gaasch L; Hannelas E; Kahn I; Pierron C; Del Lero N; Schalbar C; Do Carmo E; Kohnen M; Andlauer E; Hublart P; Masi S; de la Fuente Garcia I; Vergison A; Mossong J
Euro Surveill; 2024 Jan; 29(4):. PubMed ID: 38275017
[TBL] [Abstract][Full Text] [Related]
14. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T;
N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726
[TBL] [Abstract][Full Text] [Related]
15. Risk Analysis of Respiratory Syncytial Virus Among Infants in the United States by Birth Month.
Gantenberg JR; van Aalst R; Bhuma MR; Limone B; Diakun D; Smith DM; Nelson CB; Bengtson AM; Chaves SS; La Via WV; Rizzo C; Savitz DA; Zullo AR
J Pediatric Infect Dis Soc; 2024 Jun; 13(6):317-327. PubMed ID: 38738450
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
Bergeron HC; Tripp RA
Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
[TBL] [Abstract][Full Text] [Related]
17. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.
Wang X; Li Y; Shi T; Bont LJ; Chu HY; Zar HJ; Wahi-Singh B; Ma Y; Cong B; Sharland E; Riley RD; Deng J; Figueras-Aloy J; Heikkinen T; Jones MH; Liese JG; Markić J; Mejias A; Nunes MC; Resch B; Satav A; Yeo KT; Simões EAF; Nair H; ;
Lancet; 2024 Mar; 403(10433):1241-1253. PubMed ID: 38367641
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d'Aosta Region, Italy, in the 2023-2024 Epidemic Season.
Consolati A; Farinelli M; Serravalle P; Rollandin C; Apprato L; Esposito S; Bongiorno S
Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793800
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children.
Fly JH; Eiland LS; Stultz JS
Ann Pharmacother; 2024 Apr; ():10600280241243357. PubMed ID: 38654469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
